Schroder Investment Management Group Sells 42,750 Shares of Haemonetics Co. (NYSE:HAE)

Schroder Investment Management Group reduced its stake in shares of Haemonetics Co. (NYSE:HAE) by 4.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 894,539 shares of the medical instruments supplier’s stock after selling 42,750 shares during the quarter. Schroder Investment Management Group owned 1.78% of Haemonetics worth $69,846,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Whittier Trust Co. bought a new stake in Haemonetics during the 4th quarter valued at $62,000. Parkside Financial Bank & Trust increased its position in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after acquiring an additional 240 shares during the period. AlphaQuest LLC raised its stake in shares of Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after acquiring an additional 1,826 shares during the last quarter. KBC Group NV raised its stake in shares of Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock valued at $157,000 after acquiring an additional 712 shares during the last quarter. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Haemonetics during the third quarter worth about $204,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on HAE. Bank of America lowered Haemonetics from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $95.00 to $68.00 in a research report on Friday, February 7th. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Raymond James reiterated a “strong-buy” rating and issued a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Barrington Research decreased their price objective on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $101.22.

Haemonetics Price Performance

Shares of HAE opened at $63.65 on Tuesday. Haemonetics Co. has a fifty-two week low of $58.80 and a fifty-two week high of $97.97. The firm’s 50-day simple moving average is $65.85 and its two-hundred day simple moving average is $74.63. The stock has a market cap of $3.20 billion, a PE ratio of 25.06, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.